Tuberculous Meningitis
Conditions
Keywords
linezolid
Brief summary
Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.
Interventions
DRUGLinezolid
To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
Sponsors
Huashan Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* all patients diagnosed as TBM from the electronic medical record system.
Exclusion criteria
* Does not meet the established diagnostic criteria; * Combine other pathogen central infections; * Follow-up confirmed that the final diagnosis considers other diseases (such as tumors, autoimmune encephalitis, etc.); * Our hospital has less than one week of anti-tuberculosis treatment; * Lack of information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with Medical Research Council grade deterioration | From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Time of Glasgow Coma Scale recovered to 15 | From the beginning of anti-tuberculosis treatment to the first documented recovery, assessed up to 5 years. | — |
| Time of body temperature returns to normal | From the beginning of anti-tuberculosis treatment to the first documented recovery, assessed up to 5 years. | — |
| Number of participants with new omplications | From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years. | Hydrocephalus, cerebral infarction, epilepsy, brain abscess, tuberculoma |
Countries
China
Contacts
Primary ContactXian Zhou
Backup ContactFeng Sun
Outcome results
None listed